Ethical Considerations in Rare Disease Biospecimen Collection

Photo Credit: U.S. DoD, Army Sgt. 1st Class Tyrone C. Marshall, Jr.

Biospecimen research has transformed our understanding of rare genetic diseases, enabling discoveries that improve diagnosis, treatment, and patient care. However, collecting and using human biological samples raises profound ethical considerations that researchers must carefully navigate. From ensuring truly informed consent to protecting participant privacy and sharing research benefits, ethical biospecimen research requires thoughtful attention to principles that honor the dignity and autonomy of research participants.

In rare disease research, ethics can be even more complex. Small patient populations increase the risk that individuals could be identifiable despite de-identification efforts. The urgency families feel for research progress must be balanced against protections for potentially vulnerable participants. And when research creates commercial value, questions about fair benefit sharing become more prominent. Understanding and addressing these challenges is essential for conducting responsible biospecimen research from study design to receipt of samples.

---

Informed Consent: The Foundation of Ethical Research

Informed consent is the cornerstone of ethical biospecimen research. Participants should understand what samples will be collected, how samples and data will be used, what risks and benefits are involved, and what safeguards protect privacy. For genetic disease research, consent processes should also acknowledge that genetic information may have implications not only for the participant, but also for biological relatives.

Modern biospecimen research creates consent challenges that require transparency and clear governance:

• Future research use: If samples may be used for research questions that are not yet known, how can consent remain meaningful?
• Data linkage and re-contact: Will participants be contacted for longitudinal follow-up, additional sampling, or updated medical records?
• Commercial applications: If discoveries could lead to commercial products (diagnostics, therapeutics, companion tests), how is this disclosed?
• Incidental findings: What happens if research reveals clinically significant findings unrelated to the study?

In rare disease programs, consent should clearly describe whether collection is one-time or longitudinal, what data will accompany samples, and how governance decisions are made over time. Many studies also incorporate flexible operational models — such as direct-to-participant collection — to reduce burden while maintaining consent integrity from study design to receipt of samples.

---

Privacy Protection and Data Security

Protecting participant privacy requires safeguards for both the physical biospecimens and all associated data. Genetic information is inherently identifying — especially when combined with clinical annotation, dates, geography, and longitudinal follow-up. Even when identifiers are removed, re-identification can be possible in rare diseases due to unique variant combinations and small cohort sizes.

Ethical privacy protection typically combines multiple layers:

• Technical safeguards: encryption, role-based access, audit logs, and secure transfer/storage controls
• Administrative safeguards: clear policies for access approvals, data use agreements, and oversight committees
• Physical safeguards: controlled facilities, chain-of-custody procedures, and secure storage systems

Rare disease research also requires careful judgment about publication and data sharing. Scientific transparency is important, but detailed case descriptions (variant + phenotype + geography + age) can inadvertently enable identification. Many programs adopt controlled-access models, where sensitive data is shared through data access committees rather than open release.

---

Benefit Sharing and Return of Results

Participants contribute samples that enable scientific discoveries — and those discoveries can generate value in multiple forms: improved clinical practice, new diagnostics, novel therapies, and sometimes commercial products. Ethical frameworks increasingly emphasize benefit sharing: ensuring that participants and their communities share in the benefits of research, not only the burdens.

Benefit sharing can take multiple forms:

• Research transparency: sharing study progress and aggregate findings back to patient communities
• Community engagement: involving patient groups in research priority setting and protocol design
• Access planning: considering how resulting diagnostics or therapies might be made accessible to affected communities
• Participant experience: minimizing burden and supporting retention in longitudinal studies

Return of results is one of the most complex ethical areas in rare disease research. Programs should define policies before enrollment begins, including whether results will be returned and what types of findings qualify. Common policy approaches include:

• Clinically actionable findings only (e.g., validated results with implications for care)
• Limited return via a clinical pathway (e.g., confirmation in a CLIA-certified lab where required)
• No individual return when research assays are exploratory and not clinically validated

Incidental findings introduce additional considerations — especially findings that may affect family members or reveal unexpected relationships (including misattributed parentage). Ethical programs define escalation procedures, counseling resources, and governance decision-making in advance rather than reacting ad hoc.

---

Regulatory Compliance and Oversight

Ethical biospecimen research requires compliance with multiple regulatory and governance frameworks. Institutional Review Boards (IRBs) review protocols for participant protections, risk/benefit balance, and consent clarity. In the United States, HIPAA requirements govern use and disclosure of protected health information. International ethical principles and guidelines — such as the Declaration of Helsinki — also shape expectations for participant rights and research conduct.

When research involves children or individuals with cognitive impairment — common in some genetic diseases — additional protections are essential. Ethical frameworks typically address:

• Parental permission plus age-appropriate assent when feasible
• Minimizing risk and ensuring procedures are justified by scientific value
• Re-consent planning as minors reach adulthood
• Surrogate decision-making safeguards that reflect participant interests

Operationally, compliance and ethics are tightly tied to how samples are collected and managed. Standardized procedures, documentation, and quality systems help ensure that ethical commitments are actually delivered in practice — not just described in protocol language.

---

Equity and Access

Ethical biospecimen research must address equity: ensuring that research participation opportunities and research benefits reach all populations, not only those with the resources or proximity to participate. In rare diseases, geographic dispersion and clinical access barriers can systematically exclude rural communities, lower-income families, and populations without access to specialized centers.

Equity-focused programs often incorporate:

• Recruitment designs that intentionally include diverse populations
• Participant-friendly logistics that reduce travel and time burden
• Fair compensation that offsets real participation costs
• Transparent communication in culturally and linguistically appropriate formats

Direct-to-participant collection can be a practical mechanism to reduce geographic barriers while maintaining quality controls — supporting cohorts that better reflect patient diversity from study design to receipt of samples.

---

Ethics in Practice: What “Good” Looks Like Operationally

Ethics is not only a set of principles — it’s also a set of operational decisions. Strong rare disease biospecimen programs typically include:

• Clear governance for future sample use, data sharing, and re-contact decisions
• Robust privacy and security controls matched to rare disease identifiability risks
• Defined return-of-results pathways including counseling and confirmatory testing plans where applicable
• Participant-centric logistics that reduce burden and support retention
• Transparency and community engagement that sustains trust over time

When these elements are built into a program from the beginning, ethical protections become reliable and repeatable — rather than dependent on individual investigator practices.

---

Conclusion

Ethical considerations permeate every aspect of biospecimen research in rare genetic diseases. From initial consent through sample use, privacy protection, benefit sharing, and long-term governance, researchers must balance scientific progress with respect for participant autonomy, privacy, and dignity. By adhering to ethical principles and regulatory requirements — and by operationalizing those commitments in real workflows — research teams can advance knowledge while honoring the contributions and rights of participants and families.